U.S. markets closed
  • S&P 500

    4,166.45
    -55.41 (-1.31%)
     
  • Dow 30

    33,290.08
    -533.37 (-1.58%)
     
  • Nasdaq

    14,030.38
    -130.97 (-0.92%)
     
  • Russell 2000

    2,237.75
    -49.71 (-2.17%)
     
  • Crude Oil

    71.50
    +0.46 (+0.65%)
     
  • Gold

    1,763.90
    -10.90 (-0.61%)
     
  • Silver

    25.84
    -0.01 (-0.04%)
     
  • EUR/USD

    1.1865
    -0.0045 (-0.38%)
     
  • 10-Yr Bond

    1.4500
    -0.0610 (-4.04%)
     
  • GBP/USD

    1.3809
    -0.0115 (-0.83%)
     
  • USD/JPY

    110.1500
    -0.0810 (-0.07%)
     
  • BTC-USD

    35,495.09
    -141.14 (-0.40%)
     
  • CMC Crypto 200

    888.52
    -51.42 (-5.47%)
     
  • FTSE 100

    7,017.47
    -135.96 (-1.90%)
     
  • Nikkei 225

    28,964.08
    -54.25 (-0.19%)
     

Breakeven On The Horizon For BioHiTech Global, Inc. (NASDAQ:BHTG)

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card!

BioHiTech Global, Inc.'s (NASDAQ:BHTG): BioHiTech Global, Inc., through its subsidiaries, provides technological, biological, and mechanical engineering solutions for the control, reduction, and/or reuse of organic waste in the United States and internationally. The US$44m market-cap company announced a latest loss of -US$14.7m on 31 December 2018 for its most recent financial year result. Many investors are wondering the rate at which BHTG will turn a profit, with the big question being “when will the company breakeven?” I’ve put together a brief outline of industry analyst expectations for BHTG, its year of breakeven and its implied growth rate.

Check out our latest analysis for BioHiTech Global

Expectation from Commercial Services analysts is BHTG is on the verge of breakeven. They anticipate the company to incur a final loss in 2019, before generating positive profits of US$5.1m in 2020. BHTG is therefore projected to breakeven around a few months from now. In order to meet this breakeven date, I calculated the rate at which BHTG must grow year-on-year. It turns out an average annual growth rate of 136% is expected, which is extremely buoyant. If this rate turns out to be too aggressive, BHTG may become profitable much later than analysts predict.

NasdaqCM:BHTG Past and Future Earnings, April 5th 2019
NasdaqCM:BHTG Past and Future Earnings, April 5th 2019

I’m not going to go through company-specific developments for BHTG given that this is a high-level summary, however, take into account that by and large a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

One thing I would like to bring into light with BHTG is its debt-to-equity ratio of over 2x. Typically, debt shouldn’t exceed 40% of your equity, which in BHTG’s case, it has significantly overshot. Note that a higher debt obligation increases the risk around investing in the loss-making company.

Next Steps:

There are key fundamentals of BHTG which are not covered in this article, but I must stress again that this is merely a basic overview. For a more comprehensive look at BHTG, take a look at BHTG’s company page on Simply Wall St. I’ve also compiled a list of relevant aspects you should further research:

  1. Valuation: What is BHTG worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether BHTG is currently mispriced by the market.

  2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on BioHiTech Global’s board and the CEO’s back ground.

  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.